•  
  •  
 

Authors

Si-Si Han, Yunnan Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease Prevention and Control, Yunnan University of Chinese Medicine, Kunming,650500, China
Li-Yun Song, Yunnan Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease Prevention and Control, Yunnan University of Chinese Medicine, Kunming,650500, China
Peng-Tao Liang, Yunnan Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease Prevention and Control, Yunnan University of Chinese Medicine, Kunming,650500, China
Yin-Ying Wang, Yunnan Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease Prevention and Control, Yunnan University of Chinese Medicine, Kunming,650500, China
Yi Ying, Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing, 100089, China
Xiao-Feng Chen, Yunnan Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease Prevention and Control, Yunnan University of Chinese Medicine, Kunming,650500, China
Li Li, Yunnan Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease Prevention and Control, Yunnan University of Chinese Medicine, Kunming,650500, China
Jia-Li Yuan, Yunnan Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease Prevention and Control, Yunnan University of Chinese Medicine, Kunming,650500, China
Zhong-Shan Yang, Yunnan Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease Prevention and Control, Yunnan University of Chinese Medicine, Kunming,650500, ChinaFollow

Keywords

Chronic obstructive pulmonary disease, Inflammation, Intestinal mucosal barrier, Lung and intestinal flora, Short-chain fatty acids

Abstract

Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease characterized by various pathologicallesions and an imbalance in the microflora. The Yi-Qi-Xuan-Fei Formula (YQXF) is a clinically effective formula withpharmacological potential to delay the progression of COPD. This study aims to explore the relationship between thetherapeutic mechanism of YQXF and the microflora in COPD. Our study found that YQXF reduces inflammatory injuryand inflammatory cell infiltration in lung tissue, repairs the intestinal mucosal barrier, and enhances immune function.Additionally, YQXF regulates the pulmonary and intestinal flora by increasing the abundance of Alloprevotella, Rose-buria, Oscillibacter, and Lactobacillus, while reducing the abundance of Fusobacterium, Escherichia/Shigella, and Clostridium sensu stricto. Moreover, YQXF elevates the levels of short-chain fatty acids, which are produced by theintestinal flora. In conclusion, our findings demonstrate that YQXF reduces inflammation levels in lung tissue and re-pairs the intestinal barrier in COPD rats. Furthermore, the anti-inflammatory and tissue damage prevention effects ofYQXF are based on its intervention in the pulmonary and intestinal flora. These findings provide valuable insights intothe fundamental mechanism of the herbal formula YQXF and suggest that specifically targeting the intestinal flora could be a potential therapeutic approach for COPD.

Abstract Image

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Share

COinS